

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**FOR THE MONTH OF JUNE 2021**

**COMMISSION FILE NUMBER 001-39081**

**BioNTech SE**

(Translation of registrant's name into English)

**An der Goldgrube 12  
D-55131 Mainz  
Germany  
+49 6131-9084-0**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F: Form 20-F   
Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

**DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K**

On June 22, 2021, BioNTech SE (the “Company”) held a virtual Annual General Meeting without the physical presence of shareholders or their proxies. The voting results from the Annual General Meeting are attached hereto as Exhibit 99.1.

---

## **SIGNATURE**

Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

### **BioNTech SE**

By: /s/ Dr. Sierk Poetting  
Name: Dr. Sierk Poetting  
Title: Chief Financial Officer

Date: June 22, 2021

---

## EXHIBIT INDEX

<u>Exhibit</u>	<u>Description of Exhibit</u>
99.1	<a href="#"><u>Voting results of BioNTech Annual General Meeting 2021.</u></a>

## Voting results - Overview - Only the German version is binding

Agenda Item 2 Approval of the actions of the Management Board - accepted

139,683,231		Number of shares for which valid votes were cast (= 56.71 % of the registered share capital)
139,665,613	Yes votes	99.99 % of the valid votes cast
17,618	No votes	0.01 % of the valid votes cast

Agenda Item 3 Approval of the actions of the Supervisory Board - accepted

174,869,015		Number of shares for which valid votes were cast (= 71.00 % of the registered share capital)
174,546,675	Yes votes	99.82 % of the valid votes cast
322,340	No votes	0.18 % of the valid votes cast

Agenda Item 4 Appointment of the auditor for the 2021 financial year - accepted

179,468,511		Number of shares for which valid votes were cast (= 72.86 % of the registered share capital)
179,212,710	Yes votes	99.86 % of the valid votes cast
255,801	No votes	0.14 % of the valid votes cast

Agenda Item 5

Resolution on the revocation of the existing authorized capital and the creation of a new authorized capital (Authorized Capital 2021) against contributions in cash and/or in kind with the possibility of excluding subscription rights and corresponding amendments to the Articles of Association - accepted

179,458,549		Number of shares for which valid votes were cast (= 72.86 % of the registered share capital)
172,249,826	Yes votes	95.98 % of the valid votes cast
7,208,723	No votes	4.02 % of the valid votes cast

Agenda Item 6 Amendment of the authorization to issue stock options - accepted

179,451,731		Number of shares for which valid votes were cast (= 72.86 % of the registered share capital)
178,976,669	Yes votes	99.74 % of the valid votes cast
475,062	No votes	0.26 % of the valid votes cast

Agenda Item 7

Resolution on the partial revocation and amendment of the current authorization to issue stock options (Stock Option Program 2017/2019) and on the partial revocation of Conditional Capital ESOP 2017/2019 / Resolution on the authorization to issue stock options (Stock Option Program 2021) and on the implementation of a new Conditional Capital 2021 and corresponding amendments to the Articles of Association - accepted

179,449,615		Number of shares for which valid votes were cast (= 72.86 % of the registered share capital)
178,569,618	Yes votes	99.51 % of the valid votes cast
879,997	No votes	0.49 % of the valid votes cast

Agenda Item 8

Amendment to the existing authorization to acquire treasury shares and their use, also excluding subscription rights - accepted

179,420,084		Number of shares for which valid votes were cast (= 72.84 % of the registered share capital)
178,821,434	Yes votes	99.67 % of the valid votes cast

598,650 No votes 0.33 % of the valid votes cast  
Agenda Item 9  
Extending the authorization to acquire treasury shares and to use them, also excluding  
subscription rights - accepted

179,421,159		Number of shares for which valid votes were cast (= 72.84 % of the registered share capital)
177,245,311	Yes votes	98.79 % of the valid votes cast
2,175,848	No votes	1.21 % of the valid votes cast

---

Agenda Item 10

Resolution on the approval of the system for the compensation of the members of the  
Management Board - accepted

---

179,453,511		Number of shares for which valid votes were cast (= 72.86 % of the registered share capital)
178,335,590	Yes votes	99.38 % of the valid votes cast
1,117,921	No votes	0.62 % of the valid votes cast

---

## Voting results - Overview - Only the German version is binding

### Agenda Item 11

Resolution on the compensation and on the compensation system for the members of the Supervisory Board and an amendment of Sec. 9 para. 6 of the Articles of Association - accepted

177,349,170 capital)		Number of shares for which valid votes were cast (= 72.00 % of the registered share
177,145,624	Yes votes	99.89 % of the valid votes cast
203,546	No votes	0.11 % of the valid votes cast

### Agenda Item 12

Resolution on the revocation of the resolution of the Company's Annual General Meeting of June 26, 2020 (agenda item 8 letter d)) on the consent to the conclusion of the domination and profit and loss transfer agreement between the Company as controlling company and JPT Peptide Technologies GmbH as dependent company - accepted

179,452,623 capital)		Number of shares for which valid votes were cast (= 72.86 % of the registered share
179,428,491	Yes votes	99.99 % of the valid votes cast
24,132	No votes	0.01 % of the valid votes cast

Agenda Item 13 a) Approval of the conclusion of the domination and profit and loss transfer agreement between the Company as controlling company and JPT Peptide Technologies GmbH as dependent company - accepted

179,452,355 capital)		Number of shares for which valid votes were cast (= 72.86 % of the registered share
179,428,811	Yes votes	99.99 % of the valid votes cast
23,544	No votes	0.01 % of the valid votes cast

Agenda Item 13 b) Approval of the conclusion of the domination and profit and loss transfer agreement between the Company as controlling company with BioNTech Manufacturing Marburg GmbH as dependent company - accepted

179,455,727 capital)		Number of shares for which valid votes were cast (= 72.86 % of the registered share
179,435,690	Yes votes	99.99 % of the valid votes cast
20,037	No votes	0.01 % of the valid votes cast

Agenda Item 13 c) Approval of the conclusion of the domination and profit and loss transfer agreement between the Company as controlling company and reSano GmbH as dependent company - accepted

179,453,445 capital)		Number of shares for which valid votes were cast (= 72.86 % of the registered share
179,432,707	Yes votes	99.99 % of the valid votes cast
20,738	No votes	0.01 % of the valid votes cast